Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen Urges Balance In US Biosimilars Policy

Company Outlines Key Elements For A Successful Marketplace For Biosimilars

Executive Summary

Amgen’s recent study on biosimilars trends has outlined the importance of US policy in the success of the biosimilars marketplace, insisting on the importance of increased competition and effective reimbursement and education policies. But with interests in innovative biologics as well as biosimilars, the company has also emphasized that pro-biosimilars policies must not stifle innovation and compromise free competition.

You may also be interested in...



FDA Airs ‘Concerns’ Over IP Barriers

Senators press for sharing of FDA applications with PTO as Woodcock letter seeks collaboration on everything from PTAB to patent term extensions to ‘possible misuse of the patent system.’

Patient Organizations Urge Zero Co-Pay Policy To Lower Biosimilars Cost

A group of organizations representing patients, consumers, providers and taxpayers have extended support to the zero co-pay policy which would decrease significant barriers for prescribing lower-cost biosimilars. The stakeholders have urged the US HHS and CMS to reform Medicare payment policies, “which would allow patients better access to lower cost biosimilars.”

AAM Backs Bill To Boost Biosimilar Reimbursement

Draft US legislation that would seek to encourage biosimilar adoption by temporarily boosting reimbursement has received the backing of the AAM.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel